Case number 1:23-cv-00401
Novartis Pharmaceuticals Corporation v. Nanjing Noratech Pharmaceutical Co., Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 30, 2023 | 17 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 16 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | N/A | Pro Hac Vice Attorney Melinda R. Roberts for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-RGA et al.(mpb) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 29, 2023 | N/A | SO ORDERED, re (238 in 19-cv-2021-RGA; 81 in 22-cv-1395-RGA; 88 in 21-cv-1794-RGA; 644 in 19-cv-1979-RGA; 94 in 22-cv-451-RGA; 15 in 23-cv-401-RGA; 398 in 19-cv-2053-RGA; 173 in 21-cv-1330-RGA; 1088 in 20-md-2930-RGA; 88 in 21-cv-1760-RGA) MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts, filed by Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 6/29/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 1, 2023 | N/A | Minute Entry for proceedings held before Judge Richard G. Andrews - Rule 16(b) Conference held on 6/1/2023. Counsel for Plaintiff: D. Silver. Counsel for Defendants: D. Gattuso, D. Moore, D. Taylor, A. Ferraro, R. Weinblatt. Trial is set to begin on 12/9/2024. A Pretrial Conference is set for 11/22/2024, at 9:00 AM. A Markman hearing is set for 3/12/2024, at 9:00 AM. The parties shall submit the proposed scheduling order reflecting the rulings made at the conference. (Court Reporter Heather Triozzi.) Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(lah) (Entered: 06/01/2023) (0) |
| Jun 1, 2023 | 14 | Amended Proposed Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/1/2023 (nms). Modified on 6/2/2023 (nms). (Entered: 06/01/2023) (18) |
| Jun 1, 2023 | 13 | ORAL ORDER: Due to a scheduling conflict the Rule 16(b) Conference set for 6/1/2023, will now commence at 4:00 PM in Courtroom 6A. Signed by Judge Richard G. Andrews on 6/1/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/01/2023) (0) |
| May 30, 2023 | 12 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/30/2023 (nms). (Entered: 05/30/2023) (18) |
| May 10, 2023 | 11 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 6/1/2023, at 3:30 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 5/10/2023. Associated Cases: 1:23-cv-00401-RGA, 1:20-md-02930-RGA(nms) (Entered: 05/10/2023) (1) |
| May 3, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 05/03/2023) (1) |
| May 3, 2023 | 9 | ANSWER to 1 Complaint with Jury Demand and Affirmative Defenses, by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) Modified on 5/3/2023 (nms). (Entered: 05/03/2023) (9) |
| May 3, 2023 | N/A | CORRECTING ENTRY: The Answer filed at D.I. 9 and Disclosure Statement filed at D.I. 10 have been removed from the docket. This case is a member to a pending MDL and therefore the filings need to reflect the MDL and civil action in all case captions. Counsel is to refile the Answer and Disclosure Statement accordingly. (nms) (Entered: 05/03/2023) (0) |
| Apr 13, 2023 | N/A | Pro Hac Vice Attorney Nicholas N. Kallas and Christina Schwarz for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | 7 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Exhibit A-B) (9) |
| Apr 13, 2023 | N/A | Pro Hac Vice Attorneys Christopher E. Loh, Jared L. Stringham for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | N/A | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham, filed by Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 4/13/2023. (nms) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Main Document) (1) |
| Apr 13, 2023 | 7 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Main Document) (2) |
| Apr 13, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a) (4) |
| Apr 12, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | N/A | Remark: MDL panel has been advised. (twk) (Entered: 04/11/2023) (0) |
| Apr 10, 2023 | 6 | Summons Issued as to Nanjing Noratech Pharmaceutical Co., Limited on 4/11/2023. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,058,667. (twk) (Entered: 04/11/2023) (1) |
| Apr 10, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 6, 2023 (based upon the facts currently known to Novartis). Date of Expiration of 8,101,659 Patent: January 15, 2025. Date of Expiration of 11,058,667 Patent: May 9, 2036. Thirty Month Stay Deadline: 7/14/2023. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Exhibit A-B) (27) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Civil Cover Sheet) (3) |
| Apr 10, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 04/11/2023) (3) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Main Document) (13) |
